camptothecin has been researched along with razoxane in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (66.67) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Furue, H | 1 |
| Allan, WP; Chee, GL; Hasinoff, BB; Thampatty, P; Yalowich, JC | 1 |
| Ho, CW; Lin, RK; Liu, LF; Lyu, YL | 1 |
1 review(s) available for camptothecin and razoxane
| Article | Year |
|---|---|
[Topoisomerase inhibitors developing in Japan].
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Benzopyrans; Camptothecin; Diketopiperazines; Glycosides; Humans; Irinotecan; Neoplasms; Phenazines; Piperazines; Razoxane; Topotecan | 1993 |
2 other study(ies) available for camptothecin and razoxane
| Article | Year |
|---|---|
The cardioprotective and DNA topoisomerase II inhibitory agent dexrazoxane (ICRF-187) antagonizes camptothecin-mediated growth inhibition of Chinese hamster ovary cells by inhibition of DNA synthesis.
Topics: Animals; Camptothecin; Cardiovascular Agents; Cell Division; CHO Cells; Cricetinae; DNA; Dose-Response Relationship, Drug; Enzyme Inhibitors; Nucleic Acid Synthesis Inhibitors; Razoxane; Time Factors; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors | 1999 |
Topoisomerase IIβ deficiency enhances camptothecin-induced apoptosis.
Topics: Animals; Antineoplastic Agents; Apoptosis; Blotting, Western; Camptothecin; Cell Survival; Cells, Cultured; DNA Topoisomerases, Type II; DNA-Binding Proteins; DNA-Directed RNA Polymerases; Dose-Response Relationship, Drug; Embryo, Mammalian; Fibroblasts; Mice; Mice, Knockout; Protein Subunits; Razoxane; Topoisomerase I Inhibitors; Transcription, Genetic; Tumor Suppressor Protein p53 | 2013 |